Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice

Results from a post-marketing survey

Hiroki Kawai, Atsushi Ohtsu, Narikazu Boku, Yasuo Hamamoto, Fumio Nagashima, Manabu Muto, Yasushi Sano, Kiyomi Mera, Tomonori Yano, Toshihiko Doi, Shigeaki Yoshida

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. S-1(TS-1®), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan. A nationwide post-marketing survey for safety was carried out after its approval. The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution. Methods. Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East. S-1 was administered at 80mg/m2/day for 4 weeks, followed by a 2-week rest, repeated every 6 weeks until disease progression, unacceptable toxicity, or the patient's refusal. Results. Of the 51 patients, 41 (80%) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration. The median number of treatment courses was five. Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10% or fewer patients, and no treatment-related deaths occurred. In the 47 patients with evaluable lesions, there were 2 complete responses and 18 partial responses, with a response rate of 43%. With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33%, respectively. The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response. Conclusion. S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalGastric Cancer
Volume6
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2003 Jun 2
Externally publishedYes

Fingerprint

Marketing
Stomach Neoplasms
Safety
Survival
Histology
Neoplasm Metastasis
Cancer Care Facilities
Surveys and Questionnaires
Survivors
Disease Progression
Japan
Guidelines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Gastric cancer
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice : Results from a post-marketing survey. / Kawai, Hiroki; Ohtsu, Atsushi; Boku, Narikazu; Hamamoto, Yasuo; Nagashima, Fumio; Muto, Manabu; Sano, Yasushi; Mera, Kiyomi; Yano, Tomonori; Doi, Toshihiko; Yoshida, Shigeaki.

In: Gastric Cancer, Vol. 6, No. SUPPL. 1, 02.06.2003, p. 19-23.

Research output: Contribution to journalArticle

Kawai, H, Ohtsu, A, Boku, N, Hamamoto, Y, Nagashima, F, Muto, M, Sano, Y, Mera, K, Yano, T, Doi, T & Yoshida, S 2003, 'Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: Results from a post-marketing survey', Gastric Cancer, vol. 6, no. SUPPL. 1, pp. 19-23. https://doi.org/10.1007/s10120-003-0216-9
Kawai, Hiroki ; Ohtsu, Atsushi ; Boku, Narikazu ; Hamamoto, Yasuo ; Nagashima, Fumio ; Muto, Manabu ; Sano, Yasushi ; Mera, Kiyomi ; Yano, Tomonori ; Doi, Toshihiko ; Yoshida, Shigeaki. / Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice : Results from a post-marketing survey. In: Gastric Cancer. 2003 ; Vol. 6, No. SUPPL. 1. pp. 19-23.
@article{38797b63c072470da4943a6e40956f60,
title = "Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: Results from a post-marketing survey",
abstract = "Background. S-1(TS-1{\circledR}), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan. A nationwide post-marketing survey for safety was carried out after its approval. The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution. Methods. Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East. S-1 was administered at 80mg/m2/day for 4 weeks, followed by a 2-week rest, repeated every 6 weeks until disease progression, unacceptable toxicity, or the patient's refusal. Results. Of the 51 patients, 41 (80{\%}) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration. The median number of treatment courses was five. Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10{\%} or fewer patients, and no treatment-related deaths occurred. In the 47 patients with evaluable lesions, there were 2 complete responses and 18 partial responses, with a response rate of 43{\%}. With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33{\%}, respectively. The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response. Conclusion. S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.",
keywords = "Chemotherapy, Gastric cancer, S-1",
author = "Hiroki Kawai and Atsushi Ohtsu and Narikazu Boku and Yasuo Hamamoto and Fumio Nagashima and Manabu Muto and Yasushi Sano and Kiyomi Mera and Tomonori Yano and Toshihiko Doi and Shigeaki Yoshida",
year = "2003",
month = "6",
day = "2",
doi = "10.1007/s10120-003-0216-9",
language = "English",
volume = "6",
pages = "19--23",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice

T2 - Results from a post-marketing survey

AU - Kawai, Hiroki

AU - Ohtsu, Atsushi

AU - Boku, Narikazu

AU - Hamamoto, Yasuo

AU - Nagashima, Fumio

AU - Muto, Manabu

AU - Sano, Yasushi

AU - Mera, Kiyomi

AU - Yano, Tomonori

AU - Doi, Toshihiko

AU - Yoshida, Shigeaki

PY - 2003/6/2

Y1 - 2003/6/2

N2 - Background. S-1(TS-1®), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan. A nationwide post-marketing survey for safety was carried out after its approval. The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution. Methods. Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East. S-1 was administered at 80mg/m2/day for 4 weeks, followed by a 2-week rest, repeated every 6 weeks until disease progression, unacceptable toxicity, or the patient's refusal. Results. Of the 51 patients, 41 (80%) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration. The median number of treatment courses was five. Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10% or fewer patients, and no treatment-related deaths occurred. In the 47 patients with evaluable lesions, there were 2 complete responses and 18 partial responses, with a response rate of 43%. With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33%, respectively. The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response. Conclusion. S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.

AB - Background. S-1(TS-1®), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan. A nationwide post-marketing survey for safety was carried out after its approval. The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution. Methods. Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East. S-1 was administered at 80mg/m2/day for 4 weeks, followed by a 2-week rest, repeated every 6 weeks until disease progression, unacceptable toxicity, or the patient's refusal. Results. Of the 51 patients, 41 (80%) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration. The median number of treatment courses was five. Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10% or fewer patients, and no treatment-related deaths occurred. In the 47 patients with evaluable lesions, there were 2 complete responses and 18 partial responses, with a response rate of 43%. With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33%, respectively. The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response. Conclusion. S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.

KW - Chemotherapy

KW - Gastric cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=0038584905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038584905&partnerID=8YFLogxK

U2 - 10.1007/s10120-003-0216-9

DO - 10.1007/s10120-003-0216-9

M3 - Article

VL - 6

SP - 19

EP - 23

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - SUPPL. 1

ER -